#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14086	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2062	676.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1678	1678	T	760	T,C	700,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14086	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2062	676.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1412	1412	C	838	C	789	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14086	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2062	676.9	0	HET	.	.	.	A69G	.	69	69	A	297	297	A	798	A,G	443,310	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	716.0	0	.	n	.	0	C1176T	SNP	1176	1176	C	1547	1547	T	777	T,C	735,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	716.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1708	1708	A	811	A	756	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	716.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2342	2342	C	819	C	754	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	716.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2416	2416	A	835	A	792	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	716.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	2968	2968	C	805	C,T	757,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	16	6	blaTEM	861	124	100.0	blaTEM.l15.c30.ctg.1	286	2.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	1994	folP	852	852	99.88	folP.l15.c4.ctg.1	1571	126.5	0	.	p	.	0	E151K	NONSYN	451	453	GAA	802	804	AAA	186;188;189	A;A;A	177;179;179	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	1994	folP	852	852	99.88	folP.l15.c4.ctg.1	1571	126.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1033	1035	AGC	193;192;192	A;G;C	178;177;175	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5040	gyrA	2751	2751	99.89	gyrA.l6.c30.ctg.1	3403	147.6	0	.	p	.	0	K261del	DEL	781	781	A	1056	1056	A	170	A	154	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5040	gyrA	2751	2751	99.89	gyrA.l6.c30.ctg.1	3403	147.6	1	SNP	p	S91F	0	.	.	271	273	TCC	546	548	TCC	166;164;167	T;C;C	152;152;155	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5040	gyrA	2751	2751	99.89	gyrA.l6.c30.ctg.1	3403	147.6	1	SNP	p	D95G	0	.	.	283	285	GAC	558	560	GAC	159;162;162	G;A;C	150;152;152	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5040	gyrA	2751	2751	99.89	gyrA.l6.c30.ctg.1	3403	147.6	1	SNP	p	D95N	0	.	.	283	285	GAC	558	560	GAC	159;162;162	G;A;C	150;152;152	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1730	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1434	119.9	1	SNP	p	G45D	0	.	.	133	135	GGC	523	525	GGC	244;248;248	G;G;C	221;222;225	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	834	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	989	83.6	0	.	n	.	0	A197.	DEL	197	197	A	568	568	A	185	A	175	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4940	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2977	165.2	1	SNP	p	D86N	0	.	.	256	258	GAC	597	599	GAC	201;200;198	G;A;C	187;186;190	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4940	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2977	165.2	1	SNP	p	S87R	0	.	.	259	261	AGT	600	602	AGT	198;199;196	A;G;T	189;189;183	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4940	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2977	165.2	1	SNP	p	S87I	0	.	.	259	261	AGT	600	602	AGT	198;199;196	A;G;T	189;189;183	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4940	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2977	165.2	1	SNP	p	S87W	0	.	.	259	261	AGT	600	602	AGT	198;199;196	A;G;T	189;189;183	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4940	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2977	165.2	1	SNP	p	S88P	0	.	.	262	264	TCC	603	605	TCC	197;196;197	T,C;C;C	185,1;184;186	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4288	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2655	160.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1512	1514	GGC	205;202;199	G;G;C	189;186;179	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1183	1185	GCA	220;217;215	G;C;A	193;189;195	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1186	1188	ATC	216;215;219	A;T;C	194;188;195	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1198	1200	GTG	216;215;216	G;T;G	194;190;195	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1198	1200	GTG	216;215;216	G;T;G	194;190;195	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1702	1704	ACC	221;221;223	A;C;C	203;205;209	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1756	1758	GCG	208;208;208	G;C;G	171;155;166	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1756	1758	GCG	208;208;208	G;C;G	171;155;166	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1879	1881	GGC	194;193;193	G;G;C	182;178;179	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1888	1890	GGC	187;188;187	G;G;C	168;170;170	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4054	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2253	178.6	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1906	1908	CTG	168;169;171	C,G;T;G	136,2;135;139	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5742	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3071	186.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1606	1608	CCG	186;188;189	C;C;G	168;179;177	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2256	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1745	128.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	554	554	C	174	C	160	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	368	370	GAA	230;230;228	G;A;A	217;221;219	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	656	658	GAT	229;229;231	G,A;A;T	210,1;213;214	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	779	781	TCA	227;228;232	T;C;A	214;215;219	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	0	.	p	.	0	D212N	NONSYN	634	636	GAT	890	892	AAT	223;223;224	A;A;T	214;212;210	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	908	910	GTC	217;216;217	G;T;C	208;205;209	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	0	.	p	.	0	F222S	NONSYN	664	666	TTT	920	922	TCT	215;212;208	T;C;T	203;200;194	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1238	1240	GCA	204;207;211	G;C;A	192;195;198	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	1	SNP	p	G120K	1	.	.	358	360	AAG	614	616	AAG	227;226;224	A;A,C;G,C	214;214,1;212,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	1	SNP	p	A121D	1	.	.	361	363	GAC	617	619	GAC	227;228;226	G;A;C	214;214;212	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2770	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1443	190.6	1	SNP	p	D121N	0	.	.	361	363	GAC	617	619	GAC	227;228;226	G;A;C	214;214;212	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10376	rpoB	4179	4179	99.98	rpoB.l6.c17.ctg.1	4849	213.0	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2028	2030	AAT	230;230;229	A,C;A;T	215,1;216;215	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1080	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1072	100.2	1	SNP	p	V57M	1	.	.	169	171	ATG	575	577	ATG	205;202;201	A;T;G	198;194;194	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
